Please login to the form below

Not currently logged in
Email:
Password:

GSK completes acquisition of Steifel

GSK has acquired the total share capital of Steifel Laboratories Inc in a cash deal worth $2.9bn

GlaxoSmithKline (GSK) has acquired the total share capital of Steifel Laboratories Inc in a cash deal worth $2.9bn.

As part of the deal, GSK has assumed $400m of net debt and may, dependent on the future performance of the business, be obliged to make additional cash payments of up to $300m.

GSK will operate its new dermatology business unit under the name Steifel, a GSK company.

Charles Stiefel, chairman of Stiefel, said: "As part of GSK, we are stronger, more competitive and continue to be a driving force in dermatology around the world. We are excited to combine GSK's prescription dermatology products, such as Bactroban, Cutivate and Altabax, with Stiefel's portfolio, including brands such as Duac, Olux E and Soriatane."

In 2008, Steifel products made approximately $900m in sales. This, combined with GSK's 2008 prescription dermatology product sales of $550m, creates pro forma revenues of around $1.5m – an 8 per cent share of the global prescription dermatology market.

22nd July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics